The Effect of Etrasimod on Fecal Calprotectin and High-sensitivity C-reactive Protein: Results From the ELEVATE UC Clinical Program.

Vipul JairathDavid T RubinBram VerstocktAyhan H ÇekinMaria T AbreuCharlie W LeesMarc FellmannJohn C WoolcottCatherine CrosbyJoseph WuAbhishek BhattacharjeeDavid HermanGuibao GuBritta Siegmund

Published in: Inflammatory bowel diseases (2024)

Fecal calprotectin/hsCRP levels decreased with etrasimod treatment; ROC analyses indicated a prognostic correlation between fCAL changes during induction and short-/long-term treatment response.

Keyphrases

disease activity
rheumatoid arthritis
systemic lupus erythematosus
combination therapy
smoking cessation